SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-277985
Filing Date
2023-11-15
Accepted
2023-11-15 17:14:01
Documents
15
Period of Report
2023-11-15
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d361815d8k.htm   iXBRL 8-K 28443
2 EX-23.1 d361815dex231.htm EX-23.1 2015
3 EX-99.1 d361815dex991.htm EX-99.1 92980
4 EX-99.2 d361815dex992.htm EX-99.2 468607
  Complete submission text file 0001193125-23-277985.txt   798690

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA agle-20231115.xsd EX-101.SCH 2845
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE agle-20231115_lab.xml EX-101.LAB 18758
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE agle-20231115_pre.xml EX-101.PRE 11707
9 EXTRACTED XBRL INSTANCE DOCUMENT d361815d8k_htm.xml XML 3530
Mailing Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453 6176515940
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 231411536
SIC: 2834 Pharmaceutical Preparations